CYCC
Price
$16.04
Change
-$1.11 (-6.47%)
Updated
Jul 25 closing price
Capitalization
25.41M
RNAC
Price
$13.33
Change
-$0.13 (-0.97%)
Updated
Jul 25 closing price
Capitalization
345.97M
Interact to see
Advertisement

CYCC vs RNAC

Header iconCYCC vs RNAC Comparison
Open Charts CYCC vs RNACBanner chart's image
Cyclacel Pharmaceuticals
Price$16.04
Change-$1.11 (-6.47%)
Volume$463.44K
Capitalization25.41M
Cartesian Therapeutics
Price$13.33
Change-$0.13 (-0.97%)
Volume$38.76K
Capitalization345.97M
CYCC vs RNAC Comparison Chart in %
Loading...
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYCC vs. RNAC commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCC is a StrongBuy and RNAC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (CYCC: $16.04 vs. RNAC: $13.33)
Brand notoriety: CYCC and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCC: 11% vs. RNAC: 56%
Market capitalization -- CYCC: $25.41M vs. RNAC: $345.97M
CYCC [@Biotechnology] is valued at $25.41M. RNAC’s [@Biotechnology] market capitalization is $345.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCC’s FA Score shows that 0 FA rating(s) are green whileRNAC’s FA Score has 1 green FA rating(s).

  • CYCC’s FA Score: 0 green, 5 red.
  • RNAC’s FA Score: 1 green, 4 red.
According to our system of comparison, RNAC is a better buy in the long-term than CYCC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCC’s TA Score shows that 3 TA indicator(s) are bullish while RNAC’s TA Score has 7 bullish TA indicator(s).

  • CYCC’s TA Score: 3 bullish, 5 bearish.
  • RNAC’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RNAC is a better buy in the short-term than CYCC.

Price Growth

CYCC (@Biotechnology) experienced а +22.72% price change this week, while RNAC (@Biotechnology) price change was +12.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

CYCC is expected to report earnings on May 14, 2025.

RNAC is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNAC($346M) has a higher market cap than CYCC($25.4M). RNAC has higher P/E ratio than CYCC: RNAC (2.50) vs CYCC (0.37). RNAC YTD gains are higher at: -25.572 vs. CYCC (-82.225). CYCC has higher annual earnings (EBITDA): -12.68M vs. RNAC (-83.55M). RNAC has more cash in the bank: 180M vs. CYCC (93K). CYCC has less debt than RNAC: CYCC (9K) vs RNAC (14.1M). RNAC has higher revenues than CYCC: RNAC (34.2M) vs CYCC (14K).
CYCCRNACCYCC / RNAC
Capitalization25.4M346M7%
EBITDA-12.68M-83.55M15%
Gain YTD-82.225-25.572322%
P/E Ratio0.372.5015%
Revenue14K34.2M0%
Total Cash93K180M0%
Total Debt9K14.1M0%
FUNDAMENTALS RATINGS
CYCC vs RNAC: Fundamental Ratings
CYCC
RNAC
OUTLOOK RATING
1..100
3110
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3649
P/E GROWTH RATING
1..100
9321
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCC's Valuation (83) in the Biotechnology industry is in the same range as RNAC (99). This means that CYCC’s stock grew similarly to RNAC’s over the last 12 months.

CYCC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RNAC (100). This means that CYCC’s stock grew similarly to RNAC’s over the last 12 months.

CYCC's SMR Rating (100) in the Biotechnology industry is in the same range as RNAC (100). This means that CYCC’s stock grew similarly to RNAC’s over the last 12 months.

CYCC's Price Growth Rating (36) in the Biotechnology industry is in the same range as RNAC (49). This means that CYCC’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for CYCC (93). This means that RNAC’s stock grew significantly faster than CYCC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCCRNAC
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 9 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TOKUY9.45N/A
N/A
Tokyu Corp.
RVTI0.02N/A
N/A
Rival Technologies, Inc.
RSDEF2.39N/A
N/A
Ramsdens Holdings PLC
TRUBF5.44N/A
N/A
TRUECALLER AB
CMPGY35.46-0.25
-0.70%
Compass Group Plc

CYCC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCC has been loosely correlated with MIRM. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCC jumps, then MIRM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCC
1D Price
Change %
CYCC100%
-6.47%
MIRM - CYCC
36%
Loosely correlated
-0.65%
ORMP - CYCC
30%
Poorly correlated
-3.57%
IMMP - CYCC
27%
Poorly correlated
+1.18%
RNAC - CYCC
26%
Poorly correlated
-0.97%
ICCC - CYCC
26%
Poorly correlated
-4.89%
More